


Management of glucocorticoid-induced osteoporosis in men and women

Fragility fracture

Defined as a fracture occurring on minimal trauma after age 40 years and includes forearm, spine, hip, ribs and pelvis

- 1 Consider treatment depending on age and fracture probability
- 2 Treatments listed in alphabetical order. Vitamin D and calcium are generally regarded as adjuncts to treatment. HRT: oestrogen in postmenopausal women and testosterone in men. (L) indicates that the agent is licensed for glucocorticoid-induced osteoporosis



DEVELOPED BY:
The Bone and Tooth Society
The National Osteoporosis Society
Royal College of Physicians

PACE APPROVED JUNE 2003

Management of glucocorticoid-induced osteoporosis in men and women

General measures

- Reduce dose of glucocorticoid when possible
- Consider glucocorticoid-sparing therapy, eg azathioprine, if appropriate
- Consider alternative route of glucocorticoid administration
- Recommend good nutrition especially with adequate calcium and vitamin D
- Recommend regular weight-bearing exercise
- Maintain body weight
- Avoid tobacco use and alcohol abuse
- Assess falls risk and give advice if appropriate

Investigation

In patients with previous fragility fracture:

- FBC, ESR
- Bone and liver function tests (Ca, P, alk phos, albumin, ALT/ γ GT)
- Serum creatinine
- Serum TSH

If indicated:

- Lateral thoracic and lumbar spine X-rays
- Serum paraproteins and urine Bence Jones protein
- Isotope bone scan
- Serum FSH if hormonal status unclear (women)
- Serum testosterone, LH and SHBG (men)
- Serum 25OHD and PTH
- BMD if monitoring required.

Key to abbreviations

ALT	alanine transferase
BMD	bone mineral density
ESR	erythrocyte sedimentation rate
FBC	full blood count
FSH	follicle-stimulating hormone
γ GT	gamma glutamyl transferase
LH	luteinising hormone
25OHD	25-hydroxyvitamin D
PTH	parathyroid hormone
SHBG	sex hormone binding globulin
TSH	thyroid-stimulating hormone